Valuation: Autolus Therapeutics plc

Market Cap 64Cr 55Cr 51Cr 47Cr 88Cr 6.14TCr 89Cr 606.95Cr 236.57Cr 3.08TCr 240.83Cr 235.57Cr 10TCr P/E 2026 *
-2.99x
P/E 2027 * -3.53x
Enterprise Value 64Cr 55Cr 51Cr 47Cr 88Cr 6.14TCr 89Cr 606.95Cr 236.57Cr 3.08TCr 240.83Cr 235.57Cr 10TCr EV / Sales 2026 *
4.28x
EV / Sales 2027 * 3.33x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day-2.03%
1 week+8.56%
Current month+61.74%
1 month+72.14%
3 months+48.77%
6 months+44.31%
Current year+21.11%
1 week 2.13
Extreme 2.13
2.58
1 month 1.41
Extreme 1.41
2.58
Current year 1.18
Extreme 1.175
2.58
1 year 1.18
Extreme 1.175
2.58
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Chairman 61 01/10/2014
Director/Board Member 78 01/08/2014
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap.
29/06/26 Free

Director

79,167 0.0477%
18/03/26 Other

General Counsel

7,80,818 0.4700%
18/03/26 Other

Controller/Auditor

3,31,000 0.1992%
Change 5-day change 1-year change 3-year change Capi.($)
-2.03%+8.56%+39.31%-23.49% 65Cr
+0.90%+3.48%+41.12%+2.66% 8.25TCr
-1.69%+22.38%-23.76%-37.80% 5.84TCr
+8.86%+128.01%+439.72%+42.82% 5.32TCr
-1.46%-0.83%-1.01%+30.84% 5.22TCr
+1.74%+1.19%+13.58%+175.40% 4.85TCr
+1.13%+2.91%+55.97%-16.99% 3.17TCr
+0.46%+6.05%+48.27%+99.58% 2.58TCr
+1.19%+7.62%+8.19%+225.60% 2.25TCr
-5.74%+0.79%-1.19%+842.24% 1.7TCr
Average -0.54%+16.26%+62.02%+134.09% 3.92TCr
Weighted average by Cap. -0.09%+19.96%+74.47%+81.00%

Financials

2026 *2027 *
Net sales 15Cr 13Cr 12Cr 11Cr 21Cr 1.43TCr 21Cr 141.73Cr 55Cr 719.47Cr 56Cr 55Cr 2.38TCr 19Cr 16Cr 15Cr 14Cr 26Cr 1.84TCr 27Cr 182.07Cr 71Cr 924.28Cr 72Cr 71Cr 3.06TCr
Net income -22Cr -19Cr -18Cr -16Cr -30Cr -2.09TCr -31Cr -207.08Cr -81Cr -1.05TCr -82Cr -80Cr -3.48TCr -19Cr -16Cr -15Cr -14Cr -26Cr -1.77TCr -26Cr -175.43Cr -68Cr -890.59Cr -70Cr -68Cr -2.95TCr
Net Debt - -
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
21/26/21 $2.410 -2.03% 23,18,221
20/26/20 $2.460 -3.15% 32,54,202
19/26/19 $2.540 +10.92% 78,40,758
18/26/18 $2.290 +0.44% 33,63,410
17/26/17 $2.280 +6.05% 30,36,041
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.410USD
Average target price
8.725USD
Spread / Average Target
+262.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock